Actuate Therapeutics (NASDAQ:ACTU) Coverage Initiated at HC Wainwright

HC Wainwright started coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a research report report published on Monday, Marketbeat.com reports. The firm issued a buy rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.98) EPS.

Actuate Therapeutics Trading Down 1.5 %

NASDAQ:ACTU opened at $7.35 on Monday. The company’s 50-day moving average is $8.14 and its two-hundred day moving average is $8.06. Actuate Therapeutics has a 1-year low of $5.51 and a 1-year high of $11.73.

Hedge Funds Weigh In On Actuate Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. OMERS ADMINISTRATION Corp acquired a new position in Actuate Therapeutics in the 4th quarter valued at about $84,000. Mercer Global Advisors Inc. ADV acquired a new position in Actuate Therapeutics in the 4th quarter valued at about $130,000. Voss Capital LP acquired a new position in shares of Actuate Therapeutics in the 4th quarter worth approximately $440,000. Envestnet Asset Management Inc. acquired a new position in shares of Actuate Therapeutics in the 4th quarter worth approximately $83,000. Finally, BIOS Capital Management LP acquired a new position in shares of Actuate Therapeutics in the 4th quarter worth approximately $78,753,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.